Bliss GVS Pharma Ltd. share price target and research reports

Name: Latest research reports of Bliss GVS Pharma Ltd. authored by Choice India and published by - Trendlyne research reports.
Item: Bliss GVS Pharma Ltd.
Rating: 5
Author: Choice India

Latest analyst research reports with target prices and PDF download for BLISSGVS, BSE:506197 Bliss GVS Pharma Ltd.

Search Inside the pdf :

Bliss GVS Pharma Ltd.

15 Mar 2018

166.73

-5.22%

Bliss GVS Pharma Ltd

Buy: Bliss GVS Pharma Ltd.

Choice India

The Company has established brand operations in existing markets that provide an ideal platform to extend the Bliss GVS product portfolio and with that, build new revenue streams. On the back of significant expansion across both Pharmaceutical & Healthcare verticals, the Company could be poised for an accelerated growth At CMP of Rs. 184.8 ,Bliss GVS Ltd. is trading at a P/E multiple of 12.8(x) compared to the industry peer of 25.2(x). The company has an upside potential of 25% to 30% in the next 12 to 18 months. We arrive at a target price in range of Rs231 to Rs.240....

Number of FII/FPI investors increased from 44 to 51 in Sep 2025 qtr.

Bliss GVS Pharma Ltd.

09 Jan 2018

166.73

-5.22%

BLISS GVS PHRMA LTD

Buy: Bliss GVS Pharma Ltd.

Joindre Capital Services

Bliss GVS Pharma Ltd. is an Indian pharmaceutical company headquartered in Mumbai, India. Bgvsl primarily develops, manufactures and markets products across various therapeutic categories including Anti-fungal, Contraceptive, Laxative, Anti-haemorrhoidal, Anti-spasmodic, Anti-malarial, Anti-biotic, Anti-microbial, Anti-inflammatory, Antipyretic, Analgesic and several others.BGVSLis among the world leaders in Suppositories and Pessaries dosage forms with one of the largest portfolios in this segment. It has three decades of experience in suppositories and pessaries. BGVSL most unique product is Today Vaginal Contraceptive', a safe female contraceptive. It is the only EU-GMP certified suppositories and pessaries manufacturer in India. & its portfolio...

Number of FII/FPI investors increased from 44 to 51 in Sep 2025 qtr.

Is Bliss GVS Pharma Ltd. worth buying?

173 Votes:

Buy 80.92%

Sell 8.67%

Hold 10.4%